Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for Hepatitic C

Case ID:
C16098

Value Proposition

·      Compositions for inducing anti-HCV immune responses

·      Nucleoside-modified RNA encoding one or more HCV antigens to induce robust preventive or therapeutic adaptive immune responses against HCV

 

 

Unmet Need

·      Hepatitis C virus (HCV) infection remains a significant clinical burden and is the leading cause of liver transplantation in North America. While novel oral antiviral therapies have emerged that improve HCV management, there continues to be a strong need for prophylactic HCV vaccines to prevent the disease.

 

Technology Description

·      Researchers at Johns Hopkins University, The University of Pennsylvania, and Vanderbilt University collaboratively developed a novel lipid nanoparticle vaccine for HCV. The technology consists of HCV envelope genes (E1E2) isolated from an individual who developed broadly neutralizing antibodies and cleared HCV infection without treatment. Nucleoside-modified mRNAs expressing a sequential lineage of antigens are disclosed as immunogens to induce protective or therapeutic immune responses against HCV. The nanoparticle encapsulates this mRNA, allowing an immune response against viral antigen to be produced.

 

Stage of Development

·      In vivo data 


Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty Australia 2018256867   4/27/2018     Pending
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty Canada 3,061,326   4/27/2018     Pending
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty European Patent Office 18791120.1   4/27/2018     Pending
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty Japan 2019-558722 7464954 4/27/2018 4/10/2024 4/27/2038 Granted
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty Hong Kong 62020015170.7   4/27/2018     Pending
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus DIV: Divisional Japan 2023-207892   4/27/2018     Pending
Nucleoside-modified mRNA-lipid Nanoparticle Lineage Vaccine for Hepatitis C Virus PCT: Patent Cooperation Treaty United States 16/608,392 11,660,332 10/25/2019 5/30/2023 4/27/2038 Granted
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus CON: Continuation United States 18/310,066 12/226,471 5/1/2023 2/18/2025 4/27/2038 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum